| (in millions of euros, except for share data) | 2024 | 2023 | |
|---|---|---|---|
| Net income used to calculate headline earnings per share(1) | Net income used to calculate headline earnings per share(1)
|
Net income used to calculate headline earnings per share(1) 2024 |
Net income used to calculate headline earnings per share(1) 2023 |
| Net income attributable to holders of the Company | Net income attributable to holders of the Company
|
Net income attributable to holders of the Company 2024 1,660 |
Net income attributable to holders of the Company 2023 1,312 |
| Items excluded: | Items excluded:
|
Items excluded: 2024
|
Items excluded: 2023
|
| Amortization of intangibles from acquisitions, net of tax | Amortization of intangibles from acquisitions, net of tax
|
Amortization of intangibles from acquisitions, net of tax 2024 174 |
Amortization of intangibles from acquisitions, net of tax 2023 199 |
| Impairment loss(2), net of tax | Impairment loss(2), net of tax
|
Impairment loss(2), net of tax 2024 66 |
Impairment loss(2), net of tax 2023 115 |
| Main capital gains and losses on disposal of assets and fair value adjustment of financial assets, net of tax | Main capital gains and losses on disposal of assets and fair value adjustment of financial assets, net of tax
|
Main capital gains and losses on disposal of assets and fair value adjustment of financial assets, net of tax 2024 (14) |
Main capital gains and losses on disposal of assets and fair value adjustment of financial assets, net of tax 2023 1 |
| Revaluation of earn-out payments | Revaluation of earn-out payments
|
Revaluation of earn-out payments 2024 (35) |
Revaluation of earn-out payments 2023 (12) |
| Rosetta / Publicis Health, LLC settlement (see Note 8 and Note 22) | Rosetta / Publicis Health, LLC settlement (see Note 8 and Note 22)
|
Rosetta / Publicis Health, LLC settlement (see Note 8 and Note 22) 2024 - |
Rosetta / Publicis Health, LLC settlement (see Note 8 and Note 22) 2023 152 |
| Headline net income attributable to holders of the Company | Headline net income attributable to holders of the Company E |
Headline net income attributable to holders of the Company 2024 1,851 |
Headline net income attributable to holders of the Company 2023 1,767 |
| Impact of dilutive instruments: | Impact of dilutive instruments:
|
Impact of dilutive instruments: 2024
|
Impact of dilutive instruments: 2023
|
| Savings in financial expenses related to the conversion of debt instruments, net of tax | Savings in financial expenses related to the conversion of debt instruments, net of tax
|
Savings in financial expenses related to the conversion of debt instruments, net of tax 2024 - |
Savings in financial expenses related to the conversion of debt instruments, net of tax 2023 - |
| Headline net income attributable to holders of the Company - diluted | Headline net income attributable to holders of the Company - diluted F |
Headline net income attributable to holders of the Company - diluted 2024 1,851 |
Headline net income attributable to holders of the Company - diluted 2023 1,767 |
| Number of shares used to calculate earnings per share | Number of shares used to calculate earnings per share
|
Number of shares used to calculate earnings per share 2024
|
Number of shares used to calculate earnings per share 2023
|
| Number of shares at January 1 | Number of shares at January 1
|
Number of shares at January 1 2024 254,311,860 |
Number of shares at January 1 2023 254,311,860 |
| Shares created over the year | Shares created over the year
|
Shares created over the year 2024 - |
Shares created over the year 2023 - |
| Treasury shares to be deducted (average for the year) | Treasury shares to be deducted (average for the year)
|
Treasury shares to be deducted (average for the year) 2024 (3,634,398) |
Treasury shares to be deducted (average for the year) 2023 (3,605,375) |
| Average number of shares used for the calculation | Average number of shares used for the calculation C |
Average number of shares used for the calculation 2024 250,677,462 |
Average number of shares used for the calculation 2023 250,706,485 |
| Impact of dilutive instruments: | Impact of dilutive instruments:
|
Impact of dilutive instruments: 2024
|
Impact of dilutive instruments: 2023
|
| Free shares and dilutive stock options | Free shares and dilutive stock options
|
Free shares and dilutive stock options 2024 2,888,336 |
Free shares and dilutive stock options 2023 3,292,878 |
| Number of diluted shares (in euros) | Number of diluted shares (in euros) D |
Number of diluted shares (in euros) 2024 253,565,798 |
Number of diluted shares (in euros) 2023 253,999,363 |
| Headline earnings per share(1) | Headline earnings per share(1)
E/C |
Headline earnings per share(1)2024 7.38 |
Headline earnings per share(1)2023 7.05 |
| Headline earnings per share – diluted(1) | Headline earnings per share – diluted(1)
F/D |
Headline earnings per share – diluted(1)2024 7.30 |
Headline earnings per share – diluted(1)2023 6.96 |
